Does price reveal poor-quality drugs? Evidence from 17 countries

Journal of Health Economics

Volumn 30, Issue 6, 2011, Pages 1150-1163

  Bate, Roger ^a   Jin, Ginger Zhe ^b   Mathur, Aparna ^a  

^a AMERICAN ENTERPRISE INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Counterfeit; Medicines; Original data; Price; Signal

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTIMYCOBACTERIAL AGENT; ARTEMISININ; CHLOROQUINE; CIPROFLOXACIN; COUNTERFEIT DRUG; ERYTHROMYCIN; GENERIC DRUG; ISONIAZID; PYRIMETHAMINE PLUS SULFADOXINE; RIFAMPICIN;

COST; DATA SET; DRUG; MEDICINE;

ARTICLE; CHROMATOGRAPHY; DEVELOPING COUNTRY; DRUG COST; DRUG DESIGN; DRUG FORMULATION; DRUG MARKETING; DRUG QUALITY; DRUG SOLUBILITY; PHARMACY; QUALITY CONTROL; SOCIOECONOMICS; SPECTROMETRY;

COMMERCE; COMMUNITY PHARMACY SERVICES; COSTS AND COST ANALYSIS; COUNTERFEIT DRUGS; DEVELOPING COUNTRIES; DRUG STABILITY; DRUG STORAGE; EMPIRICAL RESEARCH; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACIES; QUALITY CONTROL;

EID: 81955162906     PISSN: 01676296     EISSN: 18791646     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2011.08.006     Document Type: Article

References (41)

1. Atella, V., Bhattacharya, J., Carbonari, L., 2008. Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy. NBER Working Paper #14567.
2. Anis A.H., Wen Q. Price Regulation of Pharmaceuticals in Canada. Journal of Health Economics 1998, 17:21-38.
3. Bate R., Hess K., Mooney L. Medicine registration and medicine quality: a preliminary analysis of key cities in emerging markets. Research and Reports in Tropical Medicine 2010, 1(December):89-93. 10.2147/RRTM.S15199.
4. Bate, R., Emily, P., Sarah, N., Alexandra, M., Lorraine, M., 2010. Drug Registration - A Necessary But Not Sufficient Condition for Good Quality Drugs - A Preliminary Analysis of 12 Countries. Africa Fighting Malaria Working Paper (Africa Fighting Malaria).
5. Bate R., Tren R., Urbach J. Still Taxed to Death: An Analysis of Taxes and Tariffs on Medicines, Vaccines and Medical Devices 2006, AEI-Brookings Joint Center for Regulatory Studies, Washington, DC.
6. Bate R., Coticelli P., Tren R., Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa-a six country study. PLoS One 2008, 3(5):e2132. 10.1371/journal.pone.0002132.
7. Bate R., Hess K. Anti-malarial drug quality in Lagos and Accra-a comparison of various quality assessments. Malaria Journal 2010, 9:157. 10.1186/1475-2875-9-157.
8. Bate R., Tren R., Mooney L., et al. Pilot study of essential drug quality in two major cities in India. PLoS One 2009, 4(6):e6003. 10.1371/journal.pone.0006003.
9. Bate R., Tren R., Hess K., Mooney L., Porter K. Pilot study comparing technologies to test for substandard drugs in field settings. African Journal of Pharmacy and Pharmacology 2009, 3(April (4)):165-170.
10. Caves, R.E., Whinston, M.D., Hurwitz, M.A., 1991. Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry. Brookings Papers on Economic Activity: Microeconomics, pp. 1-48.
11. Cockburn R., Newton P.N., Agyarko E.K., Akunyili D., White N.J. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Medicine 2005, 2(4):e100.
12. Dondorp A.M., et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Tropical Medicine and International Health 2004, 9(12):1241-1246.
13. Danzon P.M. Pharmaceutical Price Regulation 1997, AEI Press.
14. Danzon P., Chao L.-W. Cross-national price differences for pharmaceuticals: how large, and why?. Journal of Health Economics 2000, 19:159-195.
15. Danzon P., Chao L.-W. Does regulation drive out competition in pharmaceutical markets?. Journal of Law and Economics 2000, 63:311-357.
16. Frank Richard G., Salkever David S. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 1997, 6:75-90.
17. Grabowski H.G., Vernon J.M. Brand loyalty, entry, and price competition in pharmaceuticalsafter the 1984 Drug Act. Journal of Law and Economics 1992, 35:331-350.
18. Grossman G., Shapiro C. Counterfeit-product trade. American Economic Review March 1988, 59-75.
19. Grossman G., Shapiro C. Foreign counterfeiting of status goods. The Quarterly Journal of Economics 1988, 103(1):79-100.
20. IMF, World Economic Outlook Databse, October 2010 Edition. (accessed 23.02.11). http://www.imf.org/external/pubs/ft/weo/2010/02/weodata/index.aspx.
21. Jin G.Z., Kato A. Price, quality and reputation: evidence from an online field experiment. RAND Journal of Economics 2006, 37(4).
22. Klein B., Leffler K. The role of market forces in assuring contractual performance. Journal of Political Economy LXXXIX 1981, 615-641.
23. Lanjouw J.O., Cockburn I.M. New pills for poor people? Empirical evidence after GATT. World Development 2001, 29:265-289.
24. Newton P., Proux S., Green M., Smithuis F., Rozendaal J., Prakongpan S., Chotivanich K., Mayxay M., Looareesuwan S., Farrar J., Nosten F., White N.J. Fake artesunate in Southeast Asia. Lancet 2001, 357(16 June (9272)):1948-1950.
25. Oxfam, 2011. Eye on the Ball Medicine Regulation - Not IP Enforcement - Can Best Deliver Quality Medicines, 143 Oxfam Brief Paper, February 2.
26. Pazderka B. Patent protection and pharmaceutical R&D spending in Canada. Canadian Public Policy 1999, 25:29-46.
27. PricewaterhouseCoopers, 2009. UK Economic Outlook. (accessed 23.02.11). http://www.ukmediacentre.pwc.com/imagelibrary/downloadMedia.ashx%3FMediaDetailsID=1562.
28. Qian Y. Impact of entry by counterfeits. Quarterly Journal of Economics 2008, 123(4):1577-1609.
29. Qian, Y., 2010. Brand Management and Strategies Against Counterfeits, Working Paper.
30. Rizzo, J.A., Zeckhauser, R., 2005. Generic Scrip Share and the Price of Brand-Name Drugs: The Role of Consumer Choice.
31. Shapiro C. Consumer information, product quality and seller reputation. Bell Journal of Economics 1982, 20-35.
32. Stigler G.J. The economics of information. Journal of Politics Economics 1961, 69:213-225.
33. The United Nations Development Programme, 2009. Indicators-Human Development Report 2009. (accessed 25.10.10). http://hdrstats.undp.org/en/indicators/.
34. United Nations Office of Drugs and Crime, 2009. Transational Trafficking and the Rule of Law in West Africa: a Threat Assessment. United Nations Office of Drugs and Crime Website, July. (accessed 17.09.10). http://www.unodc.org/documents/data-and-analysis/Studies/West_Africa_Report_2009.pdf.
35. United Nations, Department of Economic and Social Affairs, 2009. World Urbanization Prospects: The 2009 Revision. (accessed 23.02.11). http://esa.un.org/unpd/wup/index.htm.
36. Wolinsky Asher Prices as signals of product quality. The Review of Economic Studies 1983, 50(4):647-658.
37. World Health Organization, 2003. Substandard and Counterfeit Medicines. Fact Sheet No. 275, November. http://www.who.int/mediacentre/factsheets/2003/fs275/en/.
38. World Health Organization Health Action International Africa, 2007. Anti-malarial Medicines in Kenya: Availability, Quality and Registration Status.
39. World Health Organization, 2008. Measuring medicine prices, availability, affordability and price components, 2nd edition, World Health Organization, May 2008, accessed at on February 15, 2011. http://www.who.int/medicines/areas/access/medicines_prices08/en/index.html.
40. World Health Organization, 2009. Survey of the Quality of Selected Antimalarial Medicines Circulating in Madagascar, Senegal, and Uganda, November.
41. World Health Organization, 2010. Counterfeit Medicines. Fact Sheet No. 275, January. http://www.who.int/mediacentre/factsheets/fs275/en/index.html.